Linked Life Data

21081039

Source:http://linkedlifedata.com/resource/pubmed/id/21081039

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2010-11-18
pubmed:abstractText
Non-small cell lung cancer (NSCLC) stages over IIIb still remain as an intractable disease. Survival rate of NSCLC stages over IIIb could be increased through chemotherapy and radiation, but results are not satisfactory. Oriental medicine herbal formula, HangAm-Dan (HAD) has been developed for anti-tumor purpose and several previous studies have already reported its effects. The aim of this study is to assess HAD's efficacy on prolonging the survival rate of NSCLC stages over IIIb.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1999-6187
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1009-15
pubmed:dateRevised
2011-5-5
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan.
pubmed:affiliation
East-West Cancer Center, College of Oriental Medicine, Daejeon University, Daejeon, Korea. altyhs@dju.kr?
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't